Non-Alcoholic Fatty Liver Disease (NAFLD / MASLD)

1. Clinical Overview

Summary

Non-Alcoholic Fatty Liver Disease (NAFLD), recently renamed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in 2023, is the most common chronic liver disease worldwide, affecting approximately 25-30% of the global adult population. [1,2] The condition is characterised by hepatic steatosis (≥5% hepatocyte fat accumulation) occurring in the absence of significant alcohol consumption (defined as less than 20 g/day for women, less than 30 g/day for men) and without other secondary causes of hepatic fat accumulation. [3]

NAFLD/MASLD represents a disease spectrum ranging from:

1. Simple Steatosis (NAFL/MASL) – Fat accumulation without significant inflammation (~70-80% of cases)
2. Non-Alcoholic Steatohepatitis (NASH/MASH) – Steatosis plus hepatocellular injury and inflammation (~20-30% of cases)
3. Fibrosis – Progressive scarring (F1-F4)
4. Cirrhosis – End-stage liver disease (~5-10% of NASH cases)
5. Hepatocellular Carcinoma (HCC) – Can develop in cirrhotic and non-cirrhotic NASH

The condition is strongly associated with metabolic syndrome and its components: obesity (particularly visceral adiposity), type 2 diabetes mellitus (T2DM), dyslipidaemia, and hypertension. [4] Insulin resistance is the central pathophysiological driver. Most patients remain asymptomatic until advanced disease develops. [5]

Diagnosis is typically made through imaging (ultrasonography showing hepatic steatosis) combined with exclusion of other liver diseases and significant alcohol use. Liver biopsy remains the gold standard for definitive diagnosis and staging but is reserved for specific indications. Non-invasive fibrosis assessment using FIB-4 score, Enhanced Liver Fibrosis (ELF) test, or transient elastography (Fibroscan) is now the standard approach for risk stratification. [6,7]

Management is centred on lifestyle modification, particularly achieving 7-10% body weight reduction through diet and exercise, which can lead to histological improvement in NASH and fibrosis regression. [8] Medical management focuses on controlling metabolic comorbidities. Resmetirom (a thyroid hormone receptor-beta agonist) became the first FDA-approved pharmacotherapy specifically for MASH with moderate-to-advanced fibrosis (F2-F3) in 2024. [9] Other agents with evidence include pioglitazone, vitamin E, and GLP-1 receptor agonists. [10,11]

Prognosis varies significantly: simple steatosis generally has a benign course, while NASH carries risk of progression to cirrhosis (approximately 20-30% over 10-20 years). [12] Importantly, cardiovascular disease, not liver disease, is the leading cause of mortality in NAFLD/MASLD patients, emphasising the importance of aggressive cardiovascular risk factor management. [13]

---

Key Clinical Pearls

Nomenclature Change (2023): NAFLD → MASLD; NASH → MASH. The new terminology emphasises metabolic dysfunction as the primary driver and removes potentially stigmatising "non-alcoholic" language that defines the condition by what it is not. [2]

7-10% Weight Loss is the Treatment: Sustained weight reduction of 7-10% of body weight is the most effective intervention, with histological evidence of NASH resolution and potential fibrosis regression. 5% weight loss improves steatosis; 7-10% is needed for significant necroinflammation and fibrosis benefit. [8]

FIB-4 Score as First-Line Fibrosis Assessment: Use age, AST, ALT, and platelet count to calculate FIB-4. Score less than 1.3 has excellent negative predictive value for excluding advanced fibrosis. Score greater than 2.67 warrants hepatology referral. This simple, validated tool should be applied to all NAFLD patients. [6]

Cardiovascular Disease is the Number One Killer: Patients with NAFLD/MASLD die more frequently from cardiovascular events (myocardial infarction, stroke) than from liver-related complications. Aggressive management of dyslipidaemia, hypertension, and diabetes is paramount. Statins are safe and indicated. [13]

Normal Transaminases Do NOT Exclude NAFLD or Advanced Fibrosis: ALT and AST can be normal in up to 30% of NAFLD patients, including those with advanced fibrosis. Do not rely on LFTs alone for diagnosis or risk stratification. [14]

NASH Can Progress to HCC Without Cirrhosis: Unlike many other liver diseases, NASH-related HCC can develop in non-cirrhotic livers, though this is less common. Cirrhosis remains the major risk factor for HCC in MASLD. [15]

---

2. Epidemiology

Global Burden

NAFLD/MASLD is a global health epidemic paralleling the rise in obesity and metabolic syndrome:

• Global Prevalence: Estimated at 25-30% of the general adult population, with significant geographic variation. [1]
• Regional Variation:
  • Highest in Middle East (32%) and South America (30%)
  • Lowest in Africa (13%)
  • "Western nations: 24-25%"
  • "Asia: 25-27% (increasing rapidly)"
• United Kingdom: Prevalence approximately 30% in adults
• Projected Growth: NAFLD is expected to become the leading indication for liver transplantation in Western countries by 2030

Risk Factors and Associations

Metabolic Syndrome Components

NAFLD/MASLD is strongly associated with metabolic syndrome, with most patients having ≥2 components:

Demographic Factors

• Age: Prevalence increases with age; peaks in 5th-6th decade
• Sex: Slightly higher prevalence in men pre-menopause; equal after menopause. Women have slower fibrosis progression
• Ethnicity:
  • "Highest prevalence: Hispanic/Latino populations (particularly Mexican Americans)"
  • "Intermediate: Caucasians, Asian populations"
  • "Lowest: African/African American populations (genetic protective factors, e.g., PNPLA3 variants)"

Genetic Factors

• PNPLA3 (I148M variant): Most well-established genetic risk factor; increases steatosis, NASH, fibrosis, and HCC risk
• TM6SF2: Associated with steatosis and fibrosis but paradoxically protective against cardiovascular disease
• GCKR, MBOAT7: Additional susceptibility loci identified in genome-wide association studies

Disease Spectrum and Progression Rates

Not all patients with NAFLD progress through the spectrum:

Key Prognostic Determinant: Fibrosis stage is the strongest predictor of liver-related and overall mortality. Patients with advanced fibrosis (F3-F4) have significantly worse outcomes than those with F0-F2. [12]

---

3. Pathophysiology

Overview: From Metabolic Dysfunction to Liver Injury

The pathogenesis of NAFLD/MASLD is complex and multifactorial, involving systemic metabolic dysregulation, hepatocyte lipotoxicity, inflammatory cascades, and fibrogenic pathways. The original "two-hit hypothesis" has evolved into a "multiple parallel hits" model. [16]

Lipid Accumulation (Steatosis)

Insulin Resistance is the central metabolic defect driving hepatic fat accumulation:

1. Increased Hepatic Fatty Acid Uptake:

   • Peripheral insulin resistance → lipolysis in adipose tissue → ↑ free fatty acids (FFAs) delivered to liver
   • FFAs account for ~60% of hepatic triglyceride content in NAFLD

2. De Novo Lipogenesis (DNL):

   • Hepatic insulin resistance paradoxically permits continued insulin-stimulated lipogenesis
   • Hyperinsulinaemia activates SREBP-1c and ChREBP transcription factors
   • DNL contributes ~25% of hepatic triglycerides (vs ~5% in healthy individuals)

3. Dietary Fat Contribution:

   • Contributes ~15% of hepatic triglycerides
   • High fructose consumption particularly implicated (bypasses phosphofructokinase regulation)

4. Impaired Hepatic Lipid Export:

   • Reduced VLDL secretion
   • Mitochondrial β-oxidation dysfunction

Result: Net positive hepatic lipid balance → triglyceride accumulation in hepatocytes (steatosis)

Lipotoxicity and Hepatocellular Injury (NASH)

Progression from simple steatosis to NASH involves lipotoxicity from free fatty acids and lipid metabolites:

1. Oxidative Stress:

   • Mitochondrial dysfunction and reactive oxygen species (ROS) generation
   • Lipid peroxidation products (e.g., malondialdehyde, 4-hydroxynonenal)
   • Endoplasmic reticulum (ER) stress and unfolded protein response

2. Hepatocyte Apoptosis and Ballooning:

   • Free fatty acids trigger hepatocyte cell death (apoptosis, necroptosis)
   • Ballooning degeneration (swelling of hepatocytes) is hallmark histological feature
   • Release of damage-associated molecular patterns (DAMPs)

3. Inflammation:

   • Kupffer cell (hepatic macrophage) activation
   • Recruitment of circulating monocytes/macrophages
   • Cytokine release: TNF-α, IL-1β, IL-6
   • Inflammasome activation (NLRP3)

4. Gut-Liver Axis Dysregulation:

   • Intestinal dysbiosis and increased intestinal permeability
   • Translocation of bacterial products (LPS) via portal vein
   • Activation of hepatic toll-like receptors (TLR4)

5. Adipokine Imbalance:

   • ↓ Adiponectin (insulin-sensitising, anti-inflammatory)
   • ↑ Leptin (pro-inflammatory, pro-fibrotic in liver)

Fibrosis Development

Chronic inflammation and hepatocellular injury trigger fibrogenesis:

1. Hepatic Stellate Cell (HSC) Activation:

   • Quiescent HSCs transform into myofibroblast-like cells
   • Stimulated by: TGF-β, PDGF, cytokines, oxidative stress
   • HSCs are primary collagen-producing cells in liver

2. Extracellular Matrix Deposition:

   • Collagen (types I, III) accumulation
   • Initially perisinusoidal/pericellular (zone 3)
   • Progressive portal and bridging fibrosis

3. Fibrosis Staging (NASH CRN / Kleiner System):

   • F0: No fibrosis
   • F1: Perisinusoidal or periportal fibrosis
   • F2: Perisinusoidal and portal/periportal fibrosis
   • F3: Bridging fibrosis
   • F4: Cirrhosis

4. Potential for Regression:

   • Unlike previous assumptions, fibrosis can regress with effective treatment
   • Weight loss and metabolic improvement can lead to fibrosis regression, even at advanced stages

Progression to Cirrhosis and Hepatocellular Carcinoma

• Cirrhosis: Advanced fibrosis (F4) with architectural distortion, nodule formation, and loss of liver function
• Portal Hypertension: Develops due to increased intrahepatic resistance and altered hepatic vasculature
• Hepatocellular Carcinoma (HCC):
  • "Mechanisms: Chronic inflammation, oxidative stress, genomic instability"
  • NASH-related HCC can occur in non-cirrhotic livers (10-30% of NASH-HCC cases)
  • Obesity, diabetes, and advanced age are additional HCC risk factors

Histological Features

NAFLD Activity Score (NAS): Semi-quantitative scoring system (0-8) combining steatosis (0-3), inflammation (0-3), and ballooning (0-2). NAS ≥5 correlates with NASH diagnosis, but not used in isolation. [17]

---

4. Differential Diagnosis

NAFLD/MASLD is a diagnosis of exclusion requiring:

1. Evidence of hepatic steatosis (imaging or biopsy)
2. Absence of significant alcohol consumption
3. Exclusion of other causes of steatosis or liver disease

Secondary Causes of Hepatic Steatosis

Overlap Syndromes

Patients can have concurrent liver diseases. Consider screening for viral hepatitis, autoimmune markers, and hereditary liver diseases even when NAFLD appears likely, particularly if:

• Atypical presentation
• Disproportionately elevated transaminases (ALT greater than 5x ULN)
• Rapidly progressive disease
• Young age (less than 40) without typical metabolic risk factors

---

5. Clinical Presentation

Symptoms

The majority of NAFLD/MASLD patients are asymptomatic, with the condition typically discovered incidentally through:

• Abnormal liver function tests on routine screening
• Hepatic steatosis on abdominal imaging performed for other indications
• Evaluation during assessment for metabolic syndrome or diabetes

Signs

Physical examination is often unremarkable in early NAFLD/MASLD:

Clinical Scenarios Leading to Diagnosis

1. Routine Health Check / Insurance Medical: Elevated ALT discovered on screening blood tests
2. Type 2 Diabetes Clinic: Screening LFTs reveal hepatic dysfunction
3. Imaging for Other Indication: Abdominal ultrasound for gallstones/other pathology shows "bright liver"
4. Cardiovascular Risk Assessment: Metabolic syndrome work-up includes liver evaluation
5. Advanced Presentation: Decompensated cirrhosis (ascites, variceal haemorrhage, encephalopathy) as first manifestation in undiagnosed long-standing NASH

---

6. Investigations

Diagnostic Approach

1. Confirm hepatic steatosis (imaging)
2. Exclude significant alcohol intake (history)
3. Exclude other causes of liver disease (blood tests, serology)
4. Assess disease severity and fibrosis (non-invasive tests)
5. Consider liver biopsy (selected cases only)

---

Blood Tests

Liver Function Tests (LFTs)

Critical Concept: Normal transaminases do NOT exclude NAFLD or even advanced fibrosis. Up to 30% of patients with NAFLD have persistently normal ALT, and some patients with biopsy-proven NASH and significant fibrosis have normal LFTs. [14]

Metabolic and Cardiovascular Screening

Excluding Other Liver Diseases

---

Non-Invasive Fibrosis Assessment

Fibrosis stage is the most important prognostic factor in NAFLD. Non-invasive tests (NITs) have largely replaced liver biopsy for initial risk stratification.

Serum Biomarker Scores

FIB-4 Index (Recommended First-Line)

Formula: FIB-4 = (Age × AST) / (Platelet count × √ALT)

Advantages: Simple, validated, uses routine blood tests, excellent negative predictive value. Limitations: Less accurate in young (less than 35) or older (greater than 65) patients (age-dependent). Indeterminate zone requires further testing. [6]

Enhanced Liver Fibrosis (ELF) Test

Components: Serum biomarkers (hyaluronic acid, TIMP-1, PIIINP).

NICE Guideline (NG49) recommends ELF as first-line test in UK for NAFLD fibrosis assessment (though FIB-4 increasingly used due to accessibility). [7]

NAFLD Fibrosis Score (NFS)

Formula: Complex calculation using age, BMI, diabetes status, AST, ALT, platelet count, albumin. Online calculators available.

Similar performance to FIB-4; more complex to calculate.

Imaging-Based Fibrosis Assessment

Transient Elastography (Fibroscan)

Principle: Measures liver stiffness (correlates with fibrosis) using ultrasound-based shear wave elastography.

Liver Stiffness Measurement (LSM):

Controlled Attenuation Parameter (CAP): Fibroscan simultaneously measures CAP (dB/m), which quantifies hepatic steatosis:

• CAP ≥248 dB/m: Steatosis grade ≥S1 (≥5% hepatocytes)
• CAP ≥268 dB/m: Steatosis grade ≥S2 (≥33% hepatocytes)
• CAP ≥280 dB/m: Steatosis grade S3 (≥66% hepatocytes)

Limitations: Obesity (BMI greater than 35), ascites, narrow intercostal spaces may reduce reliability. Acute hepatitis, hepatic congestion, food intake can falsely elevate LSM.

MRI-Based Techniques

• MRI-PDFF (Proton Density Fat Fraction): Gold standard for non-invasive steatosis quantification. Research use; expensive.
• MR Elastography (MRE): Superior to Fibroscan for fibrosis assessment but limited availability and higher cost.

---

Liver Ultrasound

Typical Finding: "Bright liver" or "echogenic liver" due to increased echogenicity from fat accumulation.

Features:

• Increased hepatic echogenicity (brighter than renal cortex or spleen)
• Hepatomegaly
• Posterior attenuation of ultrasound beam
• Vascular blurring (reduced visibility of hepatic and portal veins)

Limitations:

• Cannot reliably detect steatosis less than 20-30% (insensitive for mild steatosis)
• Cannot differentiate simple steatosis from NASH
• Cannot accurately stage fibrosis (may show coarse echotexture or nodularity in cirrhosis)
• Operator-dependent

Role: Initial screening test; widely available and inexpensive. Should prompt further evaluation (exclude other causes, assess fibrosis).

---

Liver Biopsy

Gold Standard for:

1. Diagnosing NASH (requires histological triad: steatosis + inflammation + ballooning)
2. Staging fibrosis (F0-F4)
3. Excluding alternative or coexisting liver diseases

Indications for Liver Biopsy in NAFLD/MASLD

Liver biopsy is NOT routinely required. Consider in selected cases:

Risks: Pain, bleeding (less than 1%), infection, rare visceral perforation. Generally safe when performed by experienced operator.

Limitations:

• Sampling error (biopsy represents 1/50,000 of liver)
• Inter-observer variability in histological interpretation
• Invasive procedure
• Cost

Histological Scoring Systems:

• NAFLD Activity Score (NAS): Steatosis (0-3) + Inflammation (0-3) + Ballooning (0-2) = 0-8. NAS ≥5 suggestive of NASH.
• Fibrosis Staging (Kleiner): F0-F4 as described previously.

---

7. Management

Overview of Management Strategy

NAFLD/MASLD management is multimodal, focusing on:

1. Lifestyle modification (weight loss, diet, exercise) – Cornerstone of therapy
2. Management of metabolic comorbidities (diabetes, dyslipidaemia, hypertension)
3. Pharmacotherapy (selected patients with NASH and significant fibrosis)
4. Surveillance and monitoring (fibrosis progression, HCC in cirrhosis)
5. Liver transplantation (end-stage disease)

No single pharmacological "cure" exists for NAFLD/MASLD. Treatment is primarily aimed at:

• Reducing hepatic fat (steatosis)
• Resolving inflammation and hepatocyte injury (NASH resolution)
• Preventing or regressing fibrosis
• Reducing cardiovascular and metabolic risk

---

Management Algorithm

┌─────────────────────────────────────────────────────────────────────┐
│                    SUSPECTED NAFLD / MASLD                          │
│  (Metabolic syndrome + Elevated LFTs / Hepatic steatosis on USS)   │
└────────────────────────────┬────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│                      CONFIRM DIAGNOSIS                              │
│                                                                     │
│  1. Rule out significant alcohol: less than 30g/day (men), less than 20g/day (women) │
│  2. Exclude other causes of liver disease:                         │
│     - Viral hepatitis (HBsAg, anti-HCV)                            │
│     - Autoimmune (ANA, ASMA, IgG)                                  │
│     - Hereditary (Ferritin/Transferrin sat, Caeruloplasmin)        │
│     - Drug-induced (Medication review)                             │
│     - Coeliac (anti-tTG)                                           │
│  3. Imaging: Ultrasound (or Fibroscan with CAP)                    │
│  4. Baseline bloods: LFTs, FBC, HbA1c, Lipids                      │
└────────────────────────────┬────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│               ASSESS FIBROSIS RISK (NON-INVASIVE)                   │
│                                                                     │
│  STEP 1: Calculate FIB-4 Score                                     │
│          (Age × AST) / (Platelets × √ALT)                          │
│                                                                     │
│  ┌──────────────────┬────────────────────┬─────────────────────┐   │
│  │  FIB-4 less than 1.3      │  FIB-4 1.3-2.67    │  FIB-4 greater than 2.67        │   │
│  │  (Low Risk)      │  (Indeterminate)   │  (High Risk)        │   │
│  └────────┬─────────┴──────────┬─────────┴──────────┬──────────┘   │
│           ↓                    ↓                    ↓               │
│      Repeat FIB-4          STEP 2:            REFER HEPATOLOGY      │
│      every 2-3 years    Fibroscan or ELF                            │
│      + Lifestyle Rx            ↓                                    │
│                     ┌──────────┴──────────┐                         │
│                     ↓                     ↓                         │
│              LSM less than 8 kPa              LSM ≥8 kPa                     │
│              or ELF less than 9.8             or ELF ≥9.8                    │
│              (Low Risk)              (Advanced Fibrosis)            │
│                  ↓                        ↓                         │
│           Repeat in 2-3y          REFER HEPATOLOGY                  │
│           + Lifestyle Rx                                            │
└─────────────────────────────────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│             LIFESTYLE MODIFICATION (ALL PATIENTS)                   │
│                                                                     │
│  **WEIGHT LOSS** (Most Effective Intervention):                    │
│    - Target: 7-10% body weight reduction                           │
│    - 5% weight loss → ↓ steatosis                                  │
│    - 7-10% weight loss → NASH resolution, fibrosis regression      │
│    - Methods: Caloric restriction, dietary counselling, exercise   │
│                                                                     │
│  **DIET**:                                                          │
│    - Mediterranean diet (preferred evidence-based diet)            │
│    - Reduce: Saturated fats, processed foods, refined sugars       │
│    - Avoid: Fructose-sweetened beverages, high-fructose corn syrup│
│    - Increase: Vegetables, fruits, whole grains, lean protein, fish│
│                                                                     │
│  **PHYSICAL ACTIVITY**:                                             │
│    - Target: 150-200 minutes/week moderate-intensity exercise      │
│    - Aerobic exercise + resistance training                        │
│    - Exercise improves NAFLD independent of weight loss            │
│                                                                     │
│  **ALCOHOL**:                                                       │
│    - Minimize or abstain (even moderate alcohol worsens outcomes)  │
│    - Mandatory abstinence if advanced fibrosis/cirrhosis           │
│                                                                     │
│  **AVOID HEPATOTOXIC MEDICATIONS**                                  │
└─────────────────────────────────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│           MANAGE METABOLIC COMORBIDITIES (ALL PATIENTS)             │
│                                                                     │
│  **TYPE 2 DIABETES**:                                               │
│    - Optimize glycaemic control (target HbA1c less than 7%)                 │
│    - Preferred agents with liver benefit:                          │
│      • GLP-1 receptor agonists (Semaglutide, Liraglutide):         │
│        Weight loss + potential direct liver benefit                │
│      • SGLT2 inhibitors (Empagliflozin, Dapagliflozin):            │
│        Weight loss, cardiovascular benefit, possible liver benefit │
│      • Pioglitazone (Thiazolidinedione): Improves NASH histology   │
│        BUT: Weight gain, fluid retention, fracture risk, bladder   │
│        cancer concern - use cautiously, weigh risks/benefits        │
│    - Metformin: Safe, standard first-line, no proven liver benefit │
│                                                                     │
│  **DYSLIPIDAEMIA**:                                                 │
│    - **Statins are SAFE and INDICATED** (common myth that they are │
│      contraindicated in NAFLD - NOT TRUE)                          │
│    - Statins reduce cardiovascular mortality (leading cause of     │
│      death in NAFLD)                                               │
│    - Monitor LFTs but mild transaminitis NOT contraindication      │
│                                                                     │
│  **HYPERTENSION**:                                                  │
│    - ACE inhibitors or ARBs preferred (may have anti-fibrotic      │
│      benefit, though not proven definitively)                      │
│                                                                     │
│  **OBESITY**:                                                       │
│    - Consider bariatric surgery if BMI ≥35 with NASH and/or        │
│      BMI ≥40 (obesity class III)                                   │
│    - Bariatric surgery leads to significant NASH improvement and   │
│      fibrosis regression in majority of patients                   │
└─────────────────────────────────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│   PHARMACOTHERAPY (Selected Patients: NASH + Fibrosis ≥F2)         │
│                                                                     │
│  **RESMETIROM (Rezdiffra)** - FDA Approved 2024:                   │
│    - Indication: MASH with moderate-to-advanced fibrosis (F2-F3)   │
│    - Mechanism: Thyroid hormone receptor-β (THR-β) agonist         │
│    - Evidence: MAESTRO-NASH trial - NASH resolution, ↓ fibrosis    │
│    - Dose: 80 mg or 100 mg PO once daily                           │
│    - Monitoring: LFTs, lipids, imaging for gallbladder (increased  │
│      biliary adverse events)                                       │
│                                                                     │
│  **PIOGLITAZONE** (Off-label for NASH):                            │
│    - Evidence: Improves NASH histology, may regress fibrosis       │
│    - Dose: 30-45 mg PO once daily                                  │
│    - Indications: Biopsy-proven NASH (with or without diabetes)    │
│    - Side Effects: Weight gain (2-3 kg), fluid retention (caution  │
│      in heart failure), bone fractures (↑ in women), bladder cancer│
│      risk (controversial), avoid in active bladder cancer          │
│    - Monitoring: Weight, oedema, bone density (if long-term use)   │
│                                                                     │
│  **VITAMIN E** (α-tocopherol):                                      │
│    - Dose: 800 IU/day                                              │
│    - Evidence: Improves NASH histology in non-diabetic patients    │
│    - Indications: Biopsy-proven NASH, NON-diabetic patients        │
│    - Concerns: Long-term safety uncertain; possible increased      │
│      all-cause mortality in some meta-analyses; possible ↑ prostate│
│      cancer risk in men                                            │
│    - NOT recommended in diabetic patients (lack of efficacy)       │
│                                                                     │
│  **GLP-1 RECEPTOR AGONISTS** (Semaglutide, Liraglutide):           │
│    - Primary indication: Type 2 diabetes, obesity                  │
│    - Emerging evidence for NASH resolution and fibrosis improvement│
│    - Weight loss mechanism contributes to liver benefit            │
│    - Trials ongoing (e.g., Semaglutide in NASH)                    │
│                                                                     │
│  **Agents NOT routinely recommended**:                              │
│    - Metformin: No proven liver histological benefit               │
│    - Ursodeoxycholic acid (UDCA): No benefit in NASH               │
│    - Vitamin D: Insufficient evidence                              │
│    - Omega-3 fatty acids: May reduce steatosis on imaging but no   │
│      improvement in inflammation or fibrosis                       │
└─────────────────────────────────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│        ADVANCED FIBROSIS / CIRRHOSIS MANAGEMENT                     │
│                                                                     │
│  **If F3-F4 fibrosis or cirrhosis established**:                   │
│                                                                     │
│  1. **HCC SURVEILLANCE**:                                           │
│     - 6-monthly abdominal ultrasound ± serum AFP                   │
│     - All cirrhotic patients (F4)                                  │
│     - Consider in advanced fibrosis (F3) depending on risk factors │
│                                                                     │
│  2. **VARICEAL SCREENING** (Cirrhosis):                             │
│     - Upper GI endoscopy (OGD) at diagnosis of cirrhosis           │
│     - Screen for oesophageal/gastric varices                       │
│     - Primary prophylaxis: Non-selective β-blockers (propranolol,  │
│       carvedilol) or variceal band ligation if large varices       │
│                                                                     │
│  3. **MANAGE PORTAL HYPERTENSION COMPLICATIONS**:                   │
│     - Ascites: Sodium restriction, diuretics (spironolactone +     │
│       furosemide), therapeutic paracentesis, albumin               │
│     - Spontaneous bacterial peritonitis (SBP): Antibiotics,        │
│       prophylaxis (ciprofloxacin, norfloxacin)                     │
│     - Hepatic encephalopathy: Lactulose, rifaximin                 │
│                                                                     │
│  4. **LIVER TRANSPLANT ASSESSMENT**:                                │
│     - Refer if decompensated cirrhosis (ascites, encephalopathy,   │
│       variceal bleeding, hepatorenal syndrome, HCC)                │
│     - Calculate MELD score (Model for End-stage Liver Disease)     │
│     - NASH is projected to become leading indication for liver     │
│       transplant in Western countries                              │
│                                                                     │
│  5. **CONTINUE LIFESTYLE MODIFICATION**:                            │
│     - Weight loss and metabolic control even in cirrhosis          │
│     - Abstinence from alcohol (mandatory)                          │
│     - Avoid hepatotoxic drugs, NSAIDs (if portal hypertension)     │
└─────────────────────────────────────────────────────────────────────┘
                             ↓
┌─────────────────────────────────────────────────────────────────────┐
│                  MONITORING AND FOLLOW-UP                           │
│                                                                     │
│  **Low-risk NAFLD (FIB-4 less than 1.3, LSM less than 8 kPa)**:                      │
│    - Repeat FIB-4 every 2-3 years                                  │
│    - Annual metabolic monitoring (HbA1c, lipids, BP, weight)       │
│    - Reinforce lifestyle modification                              │
│                                                                     │
│  **Indeterminate or moderate fibrosis (F2)**:                      │
│    - Repeat Fibroscan or FIB-4 every 1-2 years                     │
│    - Hepatology follow-up                                          │
│    - Optimize metabolic factors                                    │
│    - Consider pharmacotherapy if NASH confirmed                    │
│                                                                     │
│  **Advanced fibrosis (F3-F4) / Cirrhosis**:                        │
│    - Hepatology specialist follow-up (6-monthly)                   │
│    - HCC surveillance (6-monthly USS ± AFP)                        │
│    - Variceal screening and monitoring                             │
│    - Monitor for decompensation                                    │
└─────────────────────────────────────────────────────────────────────┘

---

Lifestyle Modification (Cornerstone of Therapy)

Weight Loss

Evidence: Weight loss is the most effective intervention for NAFLD/MASLD, with clear dose-response relationship. [8]

Methods:

• Caloric restriction: 500-1000 kcal/day deficit
• Dietary counselling: Referral to dietitian
• Behavioural modification: Goal setting, self-monitoring
• Exercise: Enhances weight loss and has independent liver benefit

Challenge: Achieving and maintaining weight loss is difficult. Average sustained weight loss in clinical practice is 3-5%, less than therapeutic target. Bariatric surgery may be required in severely obese patients.

Diet

Mediterranean Diet is the best-studied dietary pattern in NAFLD:

• High in: Vegetables, fruits, whole grains, legumes, nuts, olive oil, fish
• Moderate: Poultry, dairy
• Low: Red meat, processed foods, sweets
• Evidence: Reduces hepatic steatosis and improves insulin sensitivity independent of weight loss

Foods/Nutrients to Reduce:

• Fructose (high-fructose corn syrup, sugar-sweetened beverages): Increases de novo lipogenesis
• Saturated fats: Promote hepatic lipid accumulation and inflammation
• Processed foods and refined carbohydrates

Coffee Consumption: Observational studies suggest coffee (caffeinated) may reduce risk of fibrosis progression and HCC. Mechanism unclear. Can be encouraged (unless contraindications).

Physical Activity

Recommendation: 150-200 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming)

Benefits:

• Reduces hepatic steatosis independent of weight loss
• Improves insulin sensitivity
• Combined aerobic + resistance training superior to either alone

Evidence: Exercise alone (without weight loss) reduces liver fat by ~20-30% in intervention studies.

Alcohol

Though termed "non-alcoholic," any alcohol consumption may worsen NAFLD:

• Even moderate alcohol (within "safe" limits) associated with fibrosis progression in NAFLD
• Recommendation:
  • Minimize alcohol intake (less than 10 g/day)
  • Complete abstinence if advanced fibrosis or cirrhosis

Bariatric Surgery

Indications:

• BMI ≥35 with obesity-related comorbidities (including NASH)
• BMI ≥40 (class III obesity)
• Failed sustained weight loss with lifestyle/medical therapy

Procedures: Roux-en-Y gastric bypass, sleeve gastrectomy, adjustable gastric banding

Evidence:

• Produces sustained weight loss (25-35% total body weight)
• NASH resolution in 70-80% of patients
• Fibrosis improvement/regression in 30-50%

Risks: Surgical complications, nutritional deficiencies, need for lifelong monitoring

---

Pharmacotherapy for NASH

Resmetirom (Rezdiffra)

Mechanism: Selective thyroid hormone receptor-β (THR-β) agonist. Increases hepatic fatty acid β-oxidation and reduces lipogenesis.

Indication: FDA-approved (March 2024) for adults with MASH and moderate-to-advanced liver fibrosis (F2 or F3).

Evidence: MAESTRO-NASH Phase 3 trial:

• NASH resolution without worsening fibrosis in 26-30% (vs 10% placebo)
• Fibrosis improvement in 24-26% (vs 14% placebo) [9]

Dose: 80 mg or 100 mg orally once daily

Monitoring: LFTs, lipid profile, imaging for gallbladder/biliary changes (increased cholelithiasis and cholecystitis)

Side Effects: Diarrhoea, nausea, pruritus, gallbladder-related adverse events

Availability: Approved in USA; regulatory submissions pending in other regions (2024-2025)

Pioglitazone

Mechanism: Peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonist. Improves insulin sensitivity, reduces hepatic fat accumulation and inflammation.

Evidence: Multiple RCTs demonstrate histological improvement in NASH (resolution in ~40-50%) and potential fibrosis regression. [10]

Dose: 30-45 mg orally once daily

Indications: Off-label for biopsy-proven NASH (with or without diabetes)

Side Effects:

• Weight gain (2-3 kg average; limits benefit in obese patients)
• Fluid retention (contraindicated in NYHA class III-IV heart failure)
• Bone fractures (increased risk in women)
• Bladder cancer (controversial; avoid in active bladder cancer or high-risk patients)

Monitoring: Weight, signs of fluid retention, bone density (if long-term use)

Clinical Use: Limited by side effects; reserved for carefully selected patients

Vitamin E (α-tocopherol)

Dose: 800 IU/day (far above dietary intake)

Evidence: PIVENS trial - improved NASH histology in non-diabetic patients with biopsy-proven NASH. [11]

Indications: Biopsy-proven NASH in non-diabetic adults

Limitations:

• No benefit in diabetic patients
• Long-term safety concerns: Meta-analyses suggest possible increased all-cause mortality at high doses; possible increased prostate cancer risk in men
• Not FDA-approved for NASH (used off-label)

Recommendation: Can be considered in non-diabetic patients with biopsy-proven NASH after discussion of risks/benefits. Not first-line.

GLP-1 Receptor Agonists

Agents: Semaglutide, Liraglutide, Dulaglutide

Mechanism: Incretin mimetics; promote insulin secretion, suppress glucagon, slow gastric emptying, promote satiety → weight loss

Evidence:

• Significant weight loss (10-15% with semaglutide 2.4 mg)
• Emerging evidence for NASH resolution and fibrosis improvement
• Semaglutide trials in NASH ongoing (results expected 2024-2025)

Indications: Type 2 diabetes (licensed); obesity (semaglutide, liraglutide licensed)

NAFLD Benefit: Likely mediated primarily through weight loss; possible direct hepatic anti-inflammatory effects

Clinical Use: Increasingly used in NAFLD patients with diabetes or obesity; may become standard therapy pending trial results

SGLT2 Inhibitors

Agents: Empagliflozin, Dapagliflozin, Canagliflozin

Mechanism: Inhibit renal glucose reabsorption → glycosuria, weight loss, cardiovascular benefit

Evidence: Small trials suggest reduction in liver fat and transaminases; insufficient data for histological endpoints

Clinical Use: Useful in NAFLD patients with diabetes; liver benefit likely secondary to metabolic improvement

---

8. Complications

Liver-Related Complications

Extrahepatic Complications and Associations

NAFLD/MASLD is a systemic disease with complications beyond the liver:

---

9. Prognosis and Outcomes

Disease-Specific Prognosis

Prognosis in NAFLD/MASLD varies dramatically based on disease stage:

Most Important Prognostic Factor: Fibrosis stage. Patients with advanced fibrosis (F3-F4) have significantly increased liver-related and all-cause mortality compared to F0-F2. [12]

Cause of Death

Cardiovascular disease (CVD) is the leading cause of death in NAFLD, accounting for ~40-50% of mortality, followed by extrahepatic malignancy (~25-30%) and liver-related death (~15-20%). [13]

Clinical Implication: Aggressive management of cardiovascular risk factors (dyslipidaemia, hypertension, diabetes) is as important or more important than liver-specific interventions.

Factors Associated with Worse Prognosis

• Advanced age
• Type 2 diabetes mellitus
• Obesity (particularly visceral adiposity)
• Advanced fibrosis stage (F3-F4)
• Elevated AST:ALT ratio greater than 1 (suggests advanced fibrosis/cirrhosis)
• Thrombocytopenia (portal hypertension)
• Low albumin, prolonged PT/INR (synthetic dysfunction)

Fibrosis Progression

• Average rate of fibrosis progression: ~1 fibrosis stage per 7-14 years in NASH
• Highly variable between individuals
• Factors accelerating progression: diabetes, obesity, older age, metabolic syndrome severity
• Fibrosis can regress with effective treatment (weight loss, metabolic control, pharmacotherapy)

HCC in NASH

• NASH is a growing cause of HCC (paralleling rise in NAFLD prevalence)
• HCC incidence in NASH cirrhosis: 1-2% per year
• Unique feature: NASH-related HCC can develop in non-cirrhotic livers (10-30% of NASH-HCC), unlike most other liver diseases. Surveillance strategy challenging.
• Risk factors for HCC in NASH: Cirrhosis, diabetes, obesity, older age, Hispanic ethnicity

---

10. Evidence and Guidelines

Nomenclature Update (2023)

In June 2023, a multi-society Delphi consensus panel proposed new nomenclature:

Rationale:

• Emphasises metabolic dysfunction as the primary driver
• Removes stigmatising "non-alcoholic" terminology (defines by what it is NOT)
• Aligns with modern understanding of pathophysiology
• Cardiometabolic criteria required for diagnosis (at least 1 of 5: overweight/obesity, diabetes, hypertension, dyslipidaemia, insulin resistance) [2]

Adoption: Transition period ongoing (2023-2025). Both NAFLD and MASLD terminology currently in use.

---

Key Clinical Practice Guidelines

EASL-EASD-EASO Clinical Practice Guidelines (2016)

Organisation: European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)

Key Recommendations:

1. Lifestyle modification (weight loss 7-10%) is first-line therapy
2. Screen for NAFLD in high-risk groups (metabolic syndrome, T2DM)
3. Use non-invasive tests (FIB-4, Fibroscan, ELF) for fibrosis assessment
4. Liver biopsy reserved for diagnostic uncertainty or clinical trials
5. Manage cardiovascular risk factors aggressively
6. Pioglitazone and vitamin E may be considered in biopsy-proven NASH

Reference: Hepatology 2016;64(6):1388-1402. PMID: 27062661 [1]

(Note: Update anticipated 2024-2025)

NICE Guideline NG49 (2016)

Organisation: National Institute for Health and Care Excellence (UK)

Key Recommendations:

1. Use Enhanced Liver Fibrosis (ELF) test for assessment of advanced fibrosis in NAFLD
2. ELF score ≥10.51 indicates advanced fibrosis; refer to hepatology
3. Lifestyle advice for all NAFLD patients
4. Do not offer pharmacological treatment for NAFLD routinely outside clinical trials

Reference: NICE NG49 (July 2016) [7]

AASLD Practice Guidance (2023)

Organisation: American Association for the Study of Liver Diseases

Key Recommendations:

1. Screen for NAFLD in patients with metabolic risk factors (obesity, diabetes, metabolic syndrome)
2. Use FIB-4 as initial non-invasive test; follow with elastography or ELF if indeterminate
3. Weight loss target: 7-10% body weight
4. Treat metabolic comorbidities (diabetes, dyslipidaemia, hypertension)
5. Consider pioglitazone or vitamin E in select patients with biopsy-proven NASH
6. HCC surveillance in cirrhotic NASH patients (6-monthly ultrasound)

Reference: Hepatology 2023 (updated guidance) [18]

Multi-Society Consensus on MASLD Nomenclature (2023)

Organisations: AASLD, EASL, Asociación Latinoamericana para el Estudio del Hígado (ALEH)

Outcome: Consensus on new nomenclature (MASLD, MASH) and diagnostic criteria

Reference: Hepatology 2023. PMID: 37364790 [2]

---

Landmark Trials and Evidence

---

11. Patient and Layperson Explanation

What is Fatty Liver Disease (NAFLD/MASLD)?

Fatty liver disease means your liver has too much fat stored inside its cells. Normally, the liver has very little fat. When ≥5% of liver cells contain fat, it's called "fatty liver."

If you don't drink much alcohol (less than 2 drinks per day for men, 1 drink for women), it's called "Non-Alcoholic Fatty Liver Disease" (NAFLD). The medical term is now changing to "MASLD" (Metabolic Dysfunction-Associated Steatotic Liver Disease), which emphasises that it's linked to metabolism problems like obesity and diabetes.

---

Why Does Fatty Liver Happen?

Fatty liver is strongly linked to metabolic syndrome:

• Being overweight or obese (especially belly fat)
• Type 2 diabetes or high blood sugar
• High cholesterol and triglycerides
• High blood pressure

These conditions cause insulin resistance, which means your body doesn't respond properly to insulin (the hormone that controls blood sugar). This leads to fat building up in the liver.

---

Is Fatty Liver Serious?

It depends on the stage:

1. Simple Fatty Liver (80% of cases): Fat in the liver without inflammation. This is usually not serious and doesn't progress to serious liver disease in most people.

2. NASH (20% of cases): Fat plus inflammation and liver cell damage. This is more serious because it can lead to scarring (fibrosis) over time.

3. Fibrosis and Cirrhosis: If NASH continues for years, scar tissue builds up in the liver. Severe scarring is called cirrhosis, which can lead to liver failure and liver cancer.

Good news: Most people with fatty liver do NOT progress to cirrhosis. The liver has an amazing ability to heal if you make changes.

---

What Are the Symptoms?

Most people have NO symptoms. Fatty liver is usually discovered by accident when:

• Blood tests show elevated liver enzymes (ALT, AST)
• An ultrasound scan shows a "bright liver"
• You're being checked for diabetes or high cholesterol

Some people may feel:

• Tiredness (very common but non-specific)
• Discomfort in the upper right side of the belly (where the liver is)

If the liver disease is advanced (cirrhosis), symptoms include swelling in the legs/belly, yellowing of the eyes (jaundice), confusion, or vomiting blood. These are serious and need urgent medical attention.

---

How is Fatty Liver Diagnosed?

1. Blood Tests: Liver function tests (LFTs) may show elevated ALT or AST. But normal blood tests don't rule out fatty liver.

2. Ultrasound Scan: A simple scan that shows if your liver looks "fatty" (brighter than normal).

3. Fibroscan: A special scan that measures liver stiffness (scar tissue) and fat content. Quick and painless.

4. FIB-4 Score: A calculation using your age and blood test results to estimate if you have liver scarring.

5. Liver Biopsy: A small sample of liver tissue examined under a microscope. Only done in some cases (not routine).

---

What is the Treatment?

Lifestyle changes are the most important treatment:

1. Lose Weight

• Target: 7-10% of your body weight (e.g., if you weigh 100 kg, aim to lose 7-10 kg)
• This is the single most effective treatment
• 7-10% weight loss can reverse liver inflammation and scarring
• Methods: Healthy diet, smaller portions, regular exercise

2. Eat a Healthy Diet

• Mediterranean diet is best: lots of vegetables, fruits, whole grains, fish, olive oil
• Avoid: Sugary drinks, processed foods, fast food, sweets, excessive red meat
• Limit fructose: Found in sugar-sweetened drinks and high-fructose corn syrup (fizzy drinks, fruit juice, sweets)

3. Exercise Regularly

• Aim for 150 minutes per week (e.g., 30 minutes, 5 days per week)
• Brisk walking, swimming, cycling, dancing – anything that gets your heart rate up
• Exercise helps even if you don't lose weight

4. Control Diabetes, Cholesterol, and Blood Pressure

• Take medications as prescribed (statins, blood pressure tablets, diabetes medications)
• Myth: Statins are bad for fatty liver – NOT TRUE. Statins are safe and reduce heart attack risk.

5. Avoid or Minimize Alcohol

• Even though it's "non-alcoholic" fatty liver, alcohol can make it worse
• If you have liver scarring, stop drinking alcohol completely

6. Medications for Fatty Liver

• Resmetirom (Rezdiffra): New medication approved in 2024 for people with liver inflammation and scarring
• Pioglitazone: Diabetes medication that can help the liver (but has side effects like weight gain)
• Vitamin E: May help in some people (discuss with your doctor)
• GLP-1 medications (e.g., Semaglutide/Ozempic): Help with weight loss and diabetes; may also help the liver

Weight loss surgery (bariatric surgery) may be an option if you have severe obesity and haven't been able to lose weight with diet and exercise.

---

What Happens If I Don't Treat It?

• Simple fatty liver: Usually stays stable and doesn't cause problems
• NASH (inflammation): Can progress to liver scarring (fibrosis) over 10-20 years
• Cirrhosis (severe scarring): Can lead to liver failure, liver cancer, and need for liver transplant

Important: The biggest risk is actually heart disease, not liver disease. People with fatty liver are more likely to have heart attacks and strokes. This is why controlling blood pressure, cholesterol, and diabetes is so important.

---

Can Fatty Liver Be Reversed?

Yes! If you lose weight and improve your metabolic health, the liver can heal:

• Fat can reduce or disappear
• Inflammation can resolve
• Even scarring (fibrosis) can improve or reverse in some cases

The key is sustained lifestyle change (not a quick fix). It takes commitment, but the liver has an amazing ability to regenerate.

---

What Should I Do Next?

1. Talk to your doctor about your liver health and metabolic risk factors
2. Get tested for diabetes, cholesterol, and liver function
3. Work on weight loss (even 5% helps; 7-10% is the goal)
4. Eat a healthy diet and exercise regularly
5. Take medications as prescribed for diabetes, cholesterol, blood pressure
6. Follow up regularly to monitor your liver health (blood tests, scans)

Remember: You have control over this condition. The changes you make can improve or even reverse fatty liver disease.

---

12. Examination Focus (MRCP Part 2 / Postgraduate Exams)

High-Yield Exam Topics

1. Most Common Chronic Liver Disease Worldwide

Question: "What is the most common chronic liver disease globally?"
Answer: NAFLD/MASLD (prevalence ~25-30% of adults)

2. Definition of NAFLD/MASLD

Question: "How is NAFLD defined?"
Answer:

• Hepatic steatosis (≥5% hepatocytes) on imaging or histology
• Absence of significant alcohol consumption (less than 30 g/day men, less than 20 g/day women)
• Exclusion of other secondary causes of steatosis

3. Metabolic Syndrome Association

Question: "What percentage of patients with type 2 diabetes have NAFLD?"
Answer: Approximately 70%

Question: "What is the central pathophysiological mechanism in NAFLD?"
Answer: Insulin resistance

4. Disease Spectrum

Question: "What is the difference between NAFL and NASH?"
Answer:

• NAFL (simple steatosis): Fat accumulation only; benign course
• NASH: Steatosis + hepatocellular injury (ballooning) + inflammation; risk of fibrosis progression

Question: "What percentage of NAFLD patients have NASH?"
Answer: ~20-30%

5. Histological Diagnosis

Question: "What are the three required histological features for NASH diagnosis?"
Answer:

1. Steatosis (≥5%)
2. Hepatocyte ballooning
3. Lobular inflammation

6. Fibrosis Assessment (Non-Invasive)

Question: "What is the first-line non-invasive test for fibrosis risk stratification in NAFLD?"
Answer: FIB-4 score (Age, AST, ALT, Platelets)

Question: "A 55-year-old patient with NAFLD has FIB-4 score of 2.8. What is the next step?"
Answer: Refer to hepatology for further evaluation (FIB-4 greater than 2.67 indicates high risk of advanced fibrosis)

Question: "What does Fibroscan measure?"
Answer:

• LSM (Liver Stiffness Measurement): Correlates with fibrosis (kPa)
• CAP (Controlled Attenuation Parameter): Quantifies steatosis (dB/m)

Question: "What LSM cut-off on Fibroscan suggests advanced fibrosis/cirrhosis?"
Answer: greater than 12 kPa (advanced fibrosis F3-F4)

7. AST:ALT Ratio

Question: "What is the typical AST:ALT ratio in NAFLD vs alcoholic liver disease?"
Answer:

• NAFLD: AST:ALT less than 1 (ALT > AST)
• Alcoholic liver disease: AST:ALT greater than 2 (AST >> ALT)

Caveat: In advanced NAFLD/cirrhosis, the ratio may become greater than 1

8. Most Important Prognostic Factor

Question: "What is the strongest predictor of liver-related mortality in NAFLD?"
Answer: Fibrosis stage (F3-F4 have significantly worse outcomes)

9. Leading Cause of Death

Question: "What is the leading cause of death in patients with NAFLD?"
Answer: Cardiovascular disease (not liver-related death)

Clinical implication: Aggressive management of CVD risk factors (statins, BP control, diabetes management) is paramount

10. Lifestyle Modification

Question: "What degree of weight loss is required to improve NASH histology and fibrosis?"
Answer: 7-10% body weight reduction

• 5% weight loss improves steatosis
• 7-10% weight loss leads to NASH resolution and fibrosis regression in many patients

11. Pharmacotherapy

Question: "What is the first FDA-approved medication for NASH with fibrosis?"
Answer: Resmetirom (Rezdiffra) – thyroid hormone receptor-β agonist (approved 2024 for F2-F3 MASH)

Question: "A 50-year-old non-diabetic patient with biopsy-proven NASH asks about medications. What options have evidence?"
Answer:

• Resmetirom: If F2-F3 fibrosis
• Vitamin E 800 IU/day: May improve NASH histology in non-diabetic patients
• Pioglitazone: Improves NASH but side effects (weight gain, fractures, bladder cancer concern)

Question: "Do statins worsen NAFLD?"
Answer: NO. This is a common myth. Statins are safe in NAFLD and indicated for cardiovascular risk reduction (leading cause of death in NAFLD). Mild transaminitis is not a contraindication.

12. GLP-1 Receptor Agonists

Question: "What is the role of GLP-1 agonists (e.g., semaglutide) in NAFLD?"
Answer:

• Approved for diabetes and obesity
• Promote significant weight loss (10-15%)
• Emerging evidence for NASH resolution and fibrosis improvement
• Increasingly used in NAFLD patients with diabetes or obesity

13. HCC in NASH

Question: "Can NASH cause HCC in non-cirrhotic patients?"
Answer: Yes. Unlike most liver diseases, NASH-related HCC can develop in the absence of cirrhosis (though cirrhosis is still the major risk factor).

Question: "What HCC surveillance is recommended for NASH cirrhosis?"
Answer: 6-monthly abdominal ultrasound ± serum AFP

14. Liver Biopsy Indications

Question: "When is liver biopsy indicated in NAFLD?"
Answer:

• Diagnostic uncertainty (concern for alternative/coexisting liver disease)
• Discordant non-invasive test results
• Clinical trial enrollment (requires histological staging)
• Consideration of NASH-specific pharmacotherapy requiring confirmation

NOT routinely required for NAFLD diagnosis or management

15. Nomenclature Update (2023)

Question: "What is the new name for NAFLD?"
Answer: MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Question: "Why was the nomenclature changed?"
Answer:

• Emphasises metabolic dysfunction as primary driver
• Removes stigmatising "non-alcoholic" terminology
• Requires positive cardiometabolic criteria for diagnosis

---

Common Viva Scenarios

Viva 1: Management of Incidental NAFLD

Scenario: "A 45-year-old man with BMI 32, type 2 diabetes, and hypertension is found to have elevated ALT (95 U/L) on routine screening. Ultrasound shows hepatic steatosis. How would you manage him?"

Model Answer:

1. Confirm NAFLD diagnosis:

   • Exclude significant alcohol (detailed history)
   • Exclude other liver diseases: Viral hepatitis serology (HBV, HCV), autoimmune screen (ANA, ASMA), ferritin/transferrin saturation, coeliac serology
   • Confirm steatosis (already done – USS positive)

2. Assess fibrosis risk (most important):

   • Calculate FIB-4 score (age, AST, ALT, platelets)
   • If FIB-4 less than 1.3: Low risk; lifestyle advice, repeat in 2-3 years
   • If FIB-4 1.3-2.67: Indeterminate; perform Fibroscan or ELF test
   • If FIB-4 greater than 2.67: High risk; refer to hepatology

3. Lifestyle modification (cornerstone):

   • Weight loss goal: 7-10% (if BMI 32 = ~100 kg, aim for 7-10 kg loss)
   • Mediterranean diet, reduce fructose and processed foods
   • Exercise 150-200 min/week
   • Minimize alcohol

4. Optimize metabolic comorbidities:

   • Diabetes: Optimize glycaemic control; consider GLP-1 agonist (e.g., semaglutide) or SGLT2 inhibitor (weight loss + CV benefit)
   • Hypertension: ACE inhibitor or ARB preferred
   • Dyslipidaemia: Check lipids; start statin if indicated (statins are SAFE in NAFLD)

5. Monitor:

   • Repeat FIB-4 and LFTs in 1-2 years
   • Assess weight loss and metabolic control

Examiner Question: "His FIB-4 is 2.9. What now?"
Answer: High risk (greater than 2.67). Refer to hepatology. Likely needs Fibroscan or ELF to confirm advanced fibrosis. If F3-F4, will need HCC surveillance, variceal screening (if cirrhosis), and possibly NASH pharmacotherapy.

---

Viva 2: Statins in NAFLD

Examiner: "Should this patient with NAFLD and dyslipidaemia be started on a statin?"

Model Answer: Yes, absolutely. This is a common misconception.

• Statins are SAFE in NAFLD (even with mildly elevated transaminases)
• Cardiovascular disease is the LEADING cause of death in NAFLD (not liver disease)
• Statins reduce cardiovascular mortality
• Mild transaminase elevation is NOT a contraindication
• Monitor LFTs, but do not withhold statins based on NAFLD diagnosis alone
• Multiple studies and guidelines confirm safety and cardiovascular benefit

Examiner: "What if ALT is 3x upper limit of normal?"
Answer: Still not an absolute contraindication. Check for other causes of hepatitis. Statin can still be started with monitoring. Hold statin only if ALT greater than 5x ULN or if patient develops symptoms of hepatotoxicity.

---

Viva 3: NASH Pharmacotherapy

Scenario: "A 52-year-old woman with biopsy-proven NASH and F3 fibrosis asks about medications. She is not diabetic. What are the options?"

Model Answer:

First-line (if eligible):

• Resmetirom (Rezdiffra): First FDA-approved drug for MASH with F2-F3 fibrosis. Thyroid hormone receptor-β agonist. Dose 80-100 mg/day. Evidence: NASH resolution and fibrosis improvement in MAESTRO-NASH trial. Monitor LFTs, lipids, gallbladder.

Alternative options (off-label, discuss risks/benefits):

• Vitamin E 800 IU/day: Evidence in non-diabetic NASH (PIVENS trial). Concerns: Long-term safety unclear; possible ↑ all-cause mortality, ↑ prostate cancer risk (men). Can consider after discussing risks.
• Pioglitazone 30-45 mg/day: Improves NASH histology. Side effects: Weight gain (counterproductive), fluid retention, bone fractures, bladder cancer concern. Reserve for carefully selected patients.

Emerging/Investigational:

• GLP-1 agonists (e.g., semaglutide): Not yet licensed for NASH but trials ongoing. Can use for obesity/diabetes with likely liver benefit via weight loss.

Essential concurrent management:

• Lifestyle modification (7-10% weight loss goal)
• Cardiovascular risk management (statins, BP control)
• HCC surveillance (6-monthly USS ± AFP if F3 approaching cirrhosis)
• Variceal screening if cirrhosis develops

---

Viva 4: HCC Surveillance

Examiner: "Which NAFLD patients need HCC surveillance?"

Model Answer:

Definite indication:

• NASH cirrhosis (F4): 6-monthly abdominal ultrasound ± serum AFP
• HCC incidence ~1-2% per year in NASH cirrhosis

Consider (controversial):

• Advanced fibrosis (F3): Some guidelines suggest surveillance, especially if additional risk factors (diabetes, obesity, older age)
• Non-cirrhotic NASH: NASH can cause HCC without cirrhosis (unlike most liver diseases), but surveillance not routinely recommended (low absolute risk)

Surveillance method:

• 6-monthly abdominal ultrasound
• AFP can be added (though limited sensitivity/specificity; mainly used in combination with USS)
• If lesion detected: Triple-phase CT or MRI for characterization

Examiner: "Why is HCC surveillance challenging in NASH?"
Answer:

1. Obesity limits ultrasound quality (poor acoustic window)
2. NASH-HCC can occur in non-cirrhotic livers (difficult to identify at-risk population)
3. Large at-risk population (high prevalence of NAFLD)

---

Data Interpretation Station

Scenario:

• 58-year-old man, BMI 35, type 2 diabetes, hypertension
• ALT 78 U/L (normal 10-40), AST 52 U/L, Platelets 180 x10⁹/L
• Age: 58
• Calculate FIB-4

Calculation: FIB-4 = (Age × AST) / (Platelets × √ALT) FIB-4 = (58 × 52) / (180 × √78) FIB-4 = 3016 / (180 × 8.83) FIB-4 = 3016 / 1589.4 FIB-4 = 1.90

Interpretation: FIB-4 = 1.90 (indeterminate risk, in range 1.3-2.67)

Next step: Perform second-line fibrosis assessment – Fibroscan or Enhanced Liver Fibrosis (ELF) test

---

13. References

Primary Sources

1. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388-1402. doi:10.1016/j.jhep.2015.11.004. PMID: 27062661.

2. Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520. PMID: 37364790.

3. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-357. doi:10.1002/hep.29367. PMID: 28714183.

4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84. doi:10.1002/hep.28431. PMID: 26707365.

5. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl):S47-64. doi:10.1016/j.jhep.2014.12.012. PMID: 25920090.

6. McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740-751. doi:10.1038/ajg.2016.453. PMID: 27725652.

7. National Institute for Health and Care Excellence. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE guideline [NG49]. July 2016. Available at: https://www.nice.org.uk/guidance/ng49

8. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367-378.e5. doi:10.1053/j.gastro.2015.04.005. PMID: 25865049.

9. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000. PMID: 38324483.

10. Musso G, Cassader M, Paschetta E, Gambino R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern Med. 2017;177(5):633-640. doi:10.1001/jamainternmed.2016.9607. PMID: 28241279.

11. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685. doi:10.1056/NEJMoa0907929. PMID: 20427778.

12. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557-1565. doi:10.1002/hep.29085. PMID: 28130788.

13. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65(3):589-600. doi:10.1016/j.jhep.2016.05.013. PMID: 27212244.

14. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292. doi:10.1053/jhep.2003.50229. PMID: 12774006.

15. Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827-838. doi:10.1002/hep.28368. PMID: 26599351.

16. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836-1846. doi:10.1002/hep.24001. PMID: 21038418.

17. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321. doi:10.1002/hep.20701. PMID: 15915461.

18. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323. PMID: 36727674.

19. Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5(4):362-373. doi:10.1016/S2468-1253(19)30383-8. PMID: 32027858.

20. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537-2564. doi:10.1016/j.cell.2021.04.015. PMID: 33989548.

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult current guidelines and appropriate specialists for patient care.